Previous 10 | Next 10 |
Positive Phase 1 results in high-dose setanaxib trial PR Newswire STOCKHOLM , Jan. 18, 2021 /PRNewswire/ -- Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT), today announced positive Phase 1 data...
Agenda for Calliditas virtual R&D Day on January 20, 2021 Agenda for Calliditas virtual R&D Day on January 20, 2021 PR Newswire STOCKHOLM , Jan. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ...
Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex STOCKHOLM , Dec. 16, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) submitted a simplified public mandatory offe...
Calliditas wins the 2020 SwedenBio Award STOCKHOLM , Dec. 10, 2020 /PRNewswire/ -- The winner of this year's SwedenBIO Award was announced on Wednesday December 9 th . Calliditas Therapeutics AB (publ) ("Calliditas") received the award in recognition of its suc...
Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 STOCKHOLM , Dec. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the company will host a Capital Markets Day in Stockholm, ...
SHANGHAI, China, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, ...
Calliditas Therapeutics' nomination committee for the AGM 2021 PR Newswire STOCKHOLM, Nov. 27, 2020 STOCKHOLM , Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. ...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion...
Calliditas Therapeutics (CALT): Q3 GAAP EPS of -SEK2.77.Cash of SEK1.4BPress Release For further details see: Calliditas Therapeutics reports Q3 results
Interim Report Q3, 2020 Expansion of pipeline and positive phase 3 topline data PR Newswire STOCKHOLM, Nov. 12, 2020 STOCKHOLM , Nov. 12, 2020 /PRNewswire/ -- "On August 13 th , we announced a €19.8m acquisition of a majority stake of 62.7%...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...